
Innate Pharma S.A. IPHA
$ 1.63
-1.21%
Annual report 2024
added 02-21-2026
Innate Pharma S.A. Deferred Revenue 2011-2026 | IPHA
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Innate Pharma S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 12.5 M | 91.8 M | 82.1 M | 47.9 M | 54.9 M | - | 885 K | 1.26 M | 7.66 M | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 91.8 M | 885 K | 37.4 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M | ||
|
Rigel Pharmaceuticals
RIGL
|
1.36 M | $ 33.23 | -4.03 % | $ 584 M | ||
|
I-Mab
IMAB
|
563 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | ||
|
Acer Therapeutics
ACER
|
2.91 M | - | 2.71 % | $ 14 M | ||
|
Ampio Pharmaceuticals
AMPE
|
85.7 K | - | -11.43 % | $ 502 K | ||
|
AbCellera Biologics
ABCL
|
13.5 M | $ 3.72 | -2.75 % | $ 1.11 B | ||
|
Athersys
ATHX
|
65 K | - | 3.77 % | $ 22.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
578 K | - | - | $ 521 M | ||
|
BridgeBio Pharma
BBIO
|
7.19 M | $ 64.66 | -1.37 % | $ 12.4 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
2.62 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
1.72 M | - | -4.8 % | $ 255 M | ||
|
Adverum Biotechnologies
ADVM
|
1.85 M | - | - | $ 86.2 M | ||
|
CymaBay Therapeutics
CBAY
|
1.69 M | - | - | $ 3.45 B | ||
|
Avid Bioservices
CDMO
|
39.9 M | - | - | $ 789 M | ||
|
Certara
CERT
|
75.4 M | $ 7.16 | 1.49 % | $ 1.15 B | ||
|
Caladrius Biosciences
CLBS
|
5.1 M | - | -16.75 % | $ 25.8 M | ||
|
Alpine Immune Sciences
ALPN
|
35.6 M | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K | ||
|
Capricor Therapeutics
CAPR
|
24.3 M | $ 25.91 | -3.56 % | $ 694 M | ||
|
Codexis
CDXS
|
350 K | $ 0.99 | -3.28 % | $ 72.7 M | ||
|
CTI BioPharma Corp.
CTIC
|
912 K | - | - | $ 1.2 B | ||
|
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M | ||
|
Denali Therapeutics
DNLI
|
27.9 M | $ 20.02 | -4.67 % | $ 3.29 B | ||
|
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B |